Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

bioAffinity Technologies, Inc. - Warrant (NQ:BIAFW)

0.1220 -0.0185 (-13.17%)
Streaming Delayed Price Updated: 10:15 AM EDT, Apr 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 280
Open 0.1220
Bid (Size) 0.1053 (5)
Ask (Size) 0.1400 (1)
Prev. Close 0.1405
Today's Range 0.1220 - 0.1220
52wk Range 0.1201 - 2.900
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024
From bioAffinity Technologies, Inc.
Via Business Wire
Case Study: bioAffinity Technologies’ CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer
From bioAffinity Technologies, Inc.
Via Business Wire

Performance

YTD
-59.3%
-59.3%
1 Month
-64.8%
-64.8%
3 Month
-71.6%
-71.6%
6 Month
-89.7%
-89.7%
1 Year
-81.8%
-81.8%

More News

Read More
Case Study: bioAffinity Technologies’ Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence
From bioAffinity Technologies, Inc.
Via Business Wire
Physicians’ Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Reports Positive Results from Texas Beta Launch of CyPath® Lung
From bioAffinity Technologies, Inc.
Via Business Wire
Join bioAffinity Technologies’ Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Set for Continued Expansion in 2025
From bioAffinity Technologies, Inc.
Via Business Wire
Veterans’ Research Foundation Spotlights CyPath® Lung’s Addition to the Federal Supply Schedule
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing CyPath® Lung Sales
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Closing of Registered Direct Offering, Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Reports 217% Sales Growth in Second Quarter 2024 for CyPath® Lung
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Reports Accelerating Growth of Physician Practices Ordering CyPath® Lung Tests
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory Volumes
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies News Update
From bioAffinity Technologies, Inc.
Via Business Wire

Frequently Asked Questions

Is bioAffinity Technologies, Inc. - Warrant publicly traded?
Yes, bioAffinity Technologies, Inc. - Warrant is publicly traded.
What exchange does bioAffinity Technologies, Inc. - Warrant trade on?
bioAffinity Technologies, Inc. - Warrant trades on the Nasdaq Stock Market
What is the ticker symbol for bioAffinity Technologies, Inc. - Warrant?
The ticker symbol for bioAffinity Technologies, Inc. - Warrant is BIAFW on the Nasdaq Stock Market
What is the current price of bioAffinity Technologies, Inc. - Warrant?
The current price of bioAffinity Technologies, Inc. - Warrant is 0.1220
When was bioAffinity Technologies, Inc. - Warrant last traded?
The last trade of bioAffinity Technologies, Inc. - Warrant was at 04/10/25 10:15 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.